Biochemical markers of acromegalic activity

Area of Science:

• Endocrinology
• Biochemical Markers
• Acromegaly Research

Background:

• Acromegaly, a disorder caused by excess growth hormone, requires reliable biochemical markers for monitoring disease activity.
• Assessing acromegalic activity involves evaluating clinical status alongside biochemical parameters.

Purpose of the Study:

• To compare the effectiveness of three biochemical markers in assessing acromegalic activity against a clinical score.
• To determine the most suitable biochemical marker for routine clinical use in acromegaly management.

Main Methods:

• Compared growth hormone (GH) response to thyrotropin-releasing hormone (TRH), GH suppression after oral glucose load, and basal plasma IGF-I levels.
• Utilized a clinical score to categorize 21 acromegaly patients into three groups based on disease activity (pre-surgery, improved but active, inactive).
• Analyzed 39 observations across four parameters (clinical score and three biochemical markers).

Main Results:

• The TRH test was excluded due to inconsistent results with clinical improvement.
• Basal plasma IGF-I levels and GH suppression after oral glucose showed similar detection rates across patient groups (100% in active, 71.4% improved, 27.3% vs. 18.2% inactive).
• Both IGF-I and GH suppression tests contributed equally (5.1%) to detecting acromegalic activity.

Conclusions:

• Basal plasma IGF-I is the single best biochemical marker for detecting acromegalic activity.
• IGF-I testing is statistically as effective as GH suppression testing.
• Basal plasma IGF-I offers a simpler and more practical option for patients and laboratories compared to GH suppression tests.